person · Reporting owner

Hutton Scott

Disclosed activity across 2 companies

Tapewire entity: 65186
SEC CIK: 0001697361

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BIODESIX INCBDSX · Entity 6053	Director · President & CEO	February 20, 2026	February 23, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BIODESIX INC

Report date February 20, 2026 · Filed February 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	48,767	Ending reported balance After 2026-02-23 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-02-20 · Exercise / conversion · Acquired 4,844 · Balance 50,257 F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Row 2 · 2026-02-23 · Sale · Disposed 1,490 · Balance 48,767 F2: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F3: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $12.58 to $13.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	14,531	Reported balance After 2026-02-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-02-20 · Exercise / conversion · Disposed 4,844 · Balance 14,531 F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. F5: These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

F3: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $12.58 to $13.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.

F5: These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

SPECTRANETICS CORP

Report date August 09, 2017 · Filed August 11, 2017

Section 16 reporting ended · disclosed 2017-08-11. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Righ to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.85 · Expires 2027-01-31	Direct	Reported balance After 2017-08-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-08-09 · Disposition to issuer · Disposed 8,464 · Balance 0 F1: Per the terms of the Agreement and Plan of Merger, dated as of June 27, 2017, among the Company, Philips Holding USA Inc., a Delaware corporation, and HealthTech Merger Sub, Inc., a Delaware corporation (the "Merger Agreement"), each stock option that was outstanding and unexercised as of immediately prior to the Effective Time (as defined in the Merger Agreement), whether or not vested, was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the number of shares of Company common stock for which such stock option had not then been exercised and (ii) the excess, if any, of the 38.50 per share in cash over the exercise price per share of Company common stock subject to each such stock option, without interest and less any required withholding taxes.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2017-08-09 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-08-09 · Disposition to issuer · Disposed 15,473 · Balance 0 F2: Per the terms of the Merger Agreement, each restricted stock unit award that was outstanding as of immediately prior to the Effective Time (as defined in the Merger Agreement), was cancelled and converted into the right to receive cash in amount equal to $38.50 per share in cash, without interest and less any required withholding taxes.
Performance Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2017-08-09 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-08-09 · Disposition to issuer · Disposed 7,736 · Balance 0 F3: Per the terms of the Merger Agreement, each performance stock unit granted in 2017 that was outstanding as of immediately prior to the Effective Time (as defined in the Merger Agreement), was cancelled and converted into the right to receive cash equal to the product of (i) the number of shares of Company common stock subject to such performance stock units (assuming that any applicable performance conditions were deemed to be achieved at the target performance level) and (ii) $38.50, without interest and less any required withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Per the terms of the Agreement and Plan of Merger, dated as of June 27, 2017, among the Company, Philips Holding USA Inc., a Delaware corporation, and HealthTech Merger Sub, Inc., a Delaware corporation (the "Merger Agreement"), each stock option that was outstanding and unexercised as of immediately prior to the Effective Time (as defined in the Merger Agreement), whether or not vested, was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the number of shares of Company common stock for which such stock option had not then been exercised and (ii) the excess, if any, of the 38.50 per share in cash over the exercise price per share of Company common stock subject to each such stock option, without interest and less any required withholding taxes.

F2: Per the terms of the Merger Agreement, each restricted stock unit award that was outstanding as of immediately prior to the Effective Time (as defined in the Merger Agreement), was cancelled and converted into the right to receive cash in amount equal to $38.50 per share in cash, without interest and less any required withholding taxes.

F3: Per the terms of the Merger Agreement, each performance stock unit granted in 2017 that was outstanding as of immediately prior to the Effective Time (as defined in the Merger Agreement), was cancelled and converted into the right to receive cash equal to the product of (i) the number of shares of Company common stock subject to such performance stock units (assuming that any applicable performance conditions were deemed to be achieved at the target performance level) and (ii) $38.50, without interest and less any required withholding taxes.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 09, 2017 Filed Aug 11, 2017 14:35 UTC	SPECTRANETICS CORP SPNC · Entity 173862	Disposition to issuerStock Option (Righ to Buy) · Derivative	8,464	$12.65 Strike: $25.85	$107,069.60	Disclosure SEC source: 0001179110-17-011363 · edgar.xml · derivative · entry 1 Hutton Scott · CIK 0001697361 · General Manager, VI 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,464 shares Expires 2027-01-31 F1 · derivative.exercise_date: Per the terms of the Agreement and Plan of Merger, dated as of June 27, 2017, among the Company, Philips Holding USA Inc., a Delaware corporation, and HealthTech Merger Sub, Inc., a Delaware corporation (the "Merger Agreement"), each stock option that was outstanding and unexercised as of immediately prior to the Effective Time (as defined in the Merger Agreement), whether or not vested, was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the number of shares of Company common stock for which such stock option had not then been exercised and (ii) the excess, if any, of the 38.50 per share in cash over the exercise price per share of Company common stock subject to each such stock option, without interest and less any required withholding taxes. Read SEC document
January 31, 2017 Filed Feb 9, 2017 17:02 UTC	SPECTRANETICS CORP SPNC · Entity 173862	GrantSPNC Common Stock · Derivative	8,465	$0.00 Strike: $25.85	$0.00	Disclosure SEC source: 0000789132-17-000033 · wf-form4_148667772754116.xml · derivative · entry 2 Hutton Scott · CIK 0001697361 · General Manager, VI 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,465 Underlying: Common Stock · 8,465 shares Expires 2027-01-31 F3 · derivative.exercise_date: Grant date 1/31/2017. Options vest over four years with 25% vesting on 1/31/2018 and 6.25% vesting each calendar quarter thereafter. Options are 100% vested on 1/31/2021. Read SEC document
January 31, 2017 Filed Feb 9, 2017 17:02 UTC	SPECTRANETICS CORP SPNC · Entity 173862	GrantSPNC Restricted Stock Unit · Derivative	15,474	$0.00	$0.00	Disclosure SEC source: 0000789132-17-000033 · wf-form4_148667772754116.xml · derivative · entry 1 Hutton Scott · CIK 0001697361 · General Manager, VI 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,474 Underlying: Common Stock · 15,474 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Spectranetics common stock. F2 · derivative.exercise_date: Grant date 1/31/2017. RSUs vest 25% on each of the first four anniversaries of the grant date. RSUs are 100% vested on 1/31/2021. F2 · derivative.expiration_date: Grant date 1/31/2017. RSUs vest 25% on each of the first four anniversaries of the grant date. RSUs are 100% vested on 1/31/2021. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.